CONNECT WITH US:
Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint
Sep 28, 2022 14:15 JST
Eisai Co., Ltd. and Biogen Inc. announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab.
Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis
Sep 26, 2022 19:14 JST
Eisai Co., Ltd. and nippon medac Co., Ltd. today that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare for the indication of the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") for the treatment of rheumatoid arthritis.
Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Sep 12, 2022 14:37 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced the first presentation of results from the final analysis of the Phase 3 LEAP-002 trial investigating LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA.
Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022
Sep 12, 2022 08:00 JST
Eisai Co., Ltd. announced today results from a post hoc analysis of three randomized, pivotal, Phase 3 studies.
Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
Sep 06, 2022 09:42 JST
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13.
Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-based Assays
Aug 24, 2022 15:18 JST
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into a memorandum of understanding with C2N Diagnostics ("C2N") that will seek to build awareness about how blood-based assays in the diagnosis for people living with cognitive impairment, including Alzheimer's disease (AD), may help patients receive a timely diagnosis and appropriate treatment.
Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care
Aug 09, 2022 17:09 JST
Eisai Co., Ltd. and LIFENET INSURANCE COMPANY announced today that they have entered into a capital and business alliance agreement to collaborate in dementia and other areas, with the aim of helping reduce the burden of medical and nursing care for people living in Japan's aging society.
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022
Aug 04, 2022 08:25 JST
Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab (BAN2401) and the modeling simulation of the impact of ApoE4 genotype.
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial
Aug 04, 2022 08:05 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) today announced that the Phase 3 LEAP-002 trial investigating LENVIMA.
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series
Jul 26, 2022 09:27 JST
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 21st consecutive year since its initial inclusion in 2002.
Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022
Jul 26, 2022 08:04 JST
Eisai Co. Ltd announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab (BAN2401).
U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab
Jul 06, 2022 09:12 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab.
E.Design Insurance and Eisai Enter Into Business Alliance
Jun 28, 2022 09:20 JST
E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business alliance agreement aiming to realize a society where people can safely enjoy driving for a longer period of their lives in anticipation of the advent of super-aging society, under the theme of "Improving Brain Health (brain performance) for Safe Driving."
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
Jun 24, 2022 10:55 JST
Eisai Co., Ltd. announced today that Eisai has signed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) on June 23, 2022 in Kigali, the capital of the Republic of Rwanda, and expressed Eisai's continued support for the elimination of NTDs towards the achievement of a road map for NTDs 2021-2030 launched by the World Health Organization (WHO).
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
Jun 22, 2022 13:05 JST
Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model.
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
Jun 06, 2022 14:05 JST
Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202).
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting
Jun 03, 2022 15:37 JST
Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States.
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
May 27, 2022 11:49 JST
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from June 3 to 7.
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS
May 27, 2022 11:24 JST
Eisai Co., Ltd. announced today that it has received orphan drug designation for ultrahigh-dose mecobalamin, with a prospective indication for delaying the progression of disease and functional impairment of amyotrophic lateral sclerosis (ALS), by the Ministry of Health, Labour and Welfare (MHLW).
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
May 10, 2022 10:23 JST
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway.
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan
May 10, 2022 10:00 JST
Eisai Co., Ltd. today announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin.
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
Apr 01, 2022 13:05 JST
Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of March 31, 2022.
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
Mar 28, 2022 21:38 JST
Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication of Jyseleca, Janus Kinase (JAK) inhibitor, for the treatment of patients with active moderate-to-severe ulcerative colitis in Japan.
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
Mar 22, 2022 09:21 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually.
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen
Mar 15, 2022 12:03 JST
Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today.
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments
Mar 15, 2022 11:00 JST
Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa).
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting
Mar 11, 2022 11:15 JST
Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually.
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500)
Mar 09, 2022 15:06 JST
Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi.
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma
Mar 07, 2022 12:50 JST
Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Fujitsu Spain receives 9th award of the "Fundación Consejo España-Japón" (Spain-Japan Foundation)
Oct 05, 2022 14:13 JST
Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
Oct 04, 2022 16:44 JST
MHI Group Delivers Two Large-Capacity Centrifugal Chillers for Singapore's Marina Bay District Cooling System
Oct 04, 2022 11:58 JST
Rinnai and Toyota Start Exploring Hydrogen-Powered Cooking Methods
Oct 04, 2022 11:02 JST
Neste, Idemitsu Kosan, CHIMEI and Mitsubishi Corporation join forces to create a renewable plastics supply chain
Oct 03, 2022 17:11 JST
Rovanpera crowned youngest ever champion with TOYOTA GAZOO Racing
Oct 03, 2022 11:15 JST
Hitachi Astemo develops Steer-by-Wire prototype with advanced steering and failsafe function
Oct 03, 2022 09:30 JST
NEC Announces Progress on Environmental, Social and governance initiatives to support sustainable growth for the company and society
Sep 30, 2022 14:48 JST
Fujitsu highlights technologies to realize its vision for a sustainable world at CEATEC 2022
Sep 30, 2022 11:43 JST
Olympus Launches THUNDERBEAT Energy Device for Open Surgery
Sep 30, 2022 11:00 JST
Dell Technologies and Fujitsu Collaborate to Accelerate Open RAN Global Adoption
Sep 30, 2022 10:41 JST
MHI: Advanced light water reactor "SRZ-1200"
Sep 29, 2022 17:55 JST
AEON and CJPT Begin Logistics Improvement in Kyushu
Sep 29, 2022 17:20 JST
NTT DOCOMO and NEC Reduce Power Consumption for 5G SA Core by an Average of 72% using AWS Graviton2, Followed by a Successful Onboarding of 5G SA Core on Hybrid Cloud
Sep 29, 2022 16:50 JST
NEC and Red Hat Expand Global Collaboration to Drive IT Modernization and Digital Transformation
Sep 29, 2022 16:23 JST
NTT DOCOMO to Add Fourth Virtualized Base Station to Open RAN Verification Environment
Sep 29, 2022 11:16 JST
NEC Launches Open RAN cloud-native virtualized software suite to extend the NEC Open Networks best of breed ecosystem
Sep 29, 2022 09:11 JST
MHI and Institut Teknologi Bandung Launch Joint R&D for Ammonia-Fired Power Generation Using Gas Turbines in Indonesia
Sep 28, 2022 16:05 JST
Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint
Sep 28, 2022 15:15 JST
NEC Launches North American Innovation Hub for Open RAN
Sep 28, 2022 14:50 JST
More Latest Release >>